カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

前立腺がんPARP阻害剤のグローバル市場2023：リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他

■ 英語タイトル：Global Prostate Cancer PARP Inhibitor Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23AG11533）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23AG11533
■ 発行日：2023年8月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：98
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥501,120見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥751,680見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,002,240見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[前立腺がんPARP阻害剤のグローバル市場2023：リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Global Info Research社の最新の調査によると、前立腺がんPARP阻害剤のグローバル市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
本調査レポートは、世界の前立腺がんPARP阻害剤市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本資料の主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 前立腺がんPARP阻害剤の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

前立腺がんPARP阻害剤市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメント
・リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他

用途別セグメント
・病院、専門クリニック、その他

主要な市場プレーヤー
・AstraZeneca、Merck & Co., Inc、GSK、Pfizer、Johnson & Johnson、Takeda Pharmaceutical Company Limited、BeiGene, Inc、Jiangsu Hengrui Pharmaceuticals Co., Ltd

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、前立腺がんPARP阻害剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な前立腺がんPARP阻害剤メーカーの企業概要、2019年～2022年までの前立腺がんPARP阻害剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な前立腺がんPARP阻害剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別前立腺がんPARP阻害剤の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの前立腺がんPARP阻害剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での前立腺がんPARP阻害剤市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および前立腺がんPARP阻害剤の産業チェーンを掲載しています。
・第14、15章では、前立腺がんPARP阻害剤の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 前立腺がんPARP阻害剤の概要
– 種類別分析（2018年vs2022年vs2029年）：リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他
– 用途別分析（2018年vs2022年vs2029年）：病院、専門クリニック、その他
– 世界の前立腺がんPARP阻害剤市場規模・予測
– 世界の前立腺がんPARP阻害剤生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– AstraZeneca、Merck & Co., Inc、GSK、Pfizer、Johnson & Johnson、Takeda Pharmaceutical Company Limited、BeiGene, Inc、Jiangsu Hengrui Pharmaceuticals Co., Ltd
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他
・用途別分析2018年-2029年：病院、専門クリニック、その他
・前立腺がんPARP阻害剤の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・前立腺がんPARP阻害剤のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・前立腺がんPARP阻害剤のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・前立腺がんPARP阻害剤の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・前立腺がんPARP阻害剤の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Prostate Cancer PARP Inhibitor Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Lynparza
1.3.3 Zejula
1.3.4 Talzenna
1.3.5 Fluzoparib
1.3.6 PamiPali
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Specialty Clinic
1.4.4 other
1.5 Global Prostate Cancer PARP Inhibitor Drugs Market Size & Forecast
1.5.1 Global Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity (2018-2029)
1.5.3 Global Prostate Cancer PARP Inhibitor Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product and Services
2.1.4 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AstraZeneca Recent Developments/Updates
2.2 Merck & Co., Inc
2.2.1 Merck & Co., Inc Details
2.2.2 Merck & Co., Inc Major Business
2.2.3 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product and Services
2.2.4 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Merck & Co., Inc Recent Developments/Updates
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Prostate Cancer PARP Inhibitor Drugs Product and Services
2.3.4 GSK Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 GSK Recent Developments/Updates
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Prostate Cancer PARP Inhibitor Drugs Product and Services
2.4.4 Pfizer Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Pfizer Recent Developments/Updates
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product and Services
2.5.4 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Johnson & Johnson Recent Developments/Updates
2.6 Takeda Pharmaceutical Company Limited
2.6.1 Takeda Pharmaceutical Company Limited Details
2.6.2 Takeda Pharmaceutical Company Limited Major Business
2.6.3 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product and Services
2.6.4 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
2.7 BeiGene, Inc
2.7.1 BeiGene, Inc Details
2.7.2 BeiGene, Inc Major Business
2.7.3 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product and Services
2.7.4 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 BeiGene, Inc Recent Developments/Updates
2.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd
2.8.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Details
2.8.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Major Business
2.8.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product and Services
2.8.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments/Updates
3 Competitive Environment: Prostate Cancer PARP Inhibitor Drugs by Manufacturer
3.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Prostate Cancer PARP Inhibitor Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Prostate Cancer PARP Inhibitor Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Prostate Cancer PARP Inhibitor Drugs Manufacturer Market Share in 2022
3.5 Prostate Cancer PARP Inhibitor Drugs Market: Overall Company Footprint Analysis
3.5.1 Prostate Cancer PARP Inhibitor Drugs Market: Region Footprint
3.5.2 Prostate Cancer PARP Inhibitor Drugs Market: Company Product Type Footprint
3.5.3 Prostate Cancer PARP Inhibitor Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Prostate Cancer PARP Inhibitor Drugs Market Size by Region
4.1.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2018-2029)
4.2 North America Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029)
4.3 Europe Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029)
4.5 South America Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2029)
5.2 Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Type (2018-2029)
5.3 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2029)
6.2 Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Application (2018-2029)
6.3 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2029)
7.2 North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2029)
7.3 North America Prostate Cancer PARP Inhibitor Drugs Market Size by Country
7.3.1 North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Prostate Cancer PARP Inhibitor Drugs Market Size by Country
8.3.1 Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Market Size by Region
9.3.1 Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2029)
10.2 South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2029)
10.3 South America Prostate Cancer PARP Inhibitor Drugs Market Size by Country
10.3.1 South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Market Size by Country
11.3.1 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Prostate Cancer PARP Inhibitor Drugs Market Drivers
12.2 Prostate Cancer PARP Inhibitor Drugs Market Restraints
12.3 Prostate Cancer PARP Inhibitor Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Prostate Cancer PARP Inhibitor Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Prostate Cancer PARP Inhibitor Drugs
13.3 Prostate Cancer PARP Inhibitor Drugs Production Process
13.4 Prostate Cancer PARP Inhibitor Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Prostate Cancer PARP Inhibitor Drugs Typical Distributors
14.3 Prostate Cancer PARP Inhibitor Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 6. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AstraZeneca Recent Developments/Updates
Table 8. Merck & Co., Inc Basic Information, Manufacturing Base and Competitors
Table 9. Merck & Co., Inc Major Business
Table 10. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 11. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Merck & Co., Inc Recent Developments/Updates
Table 13. GSK Basic Information, Manufacturing Base and Competitors
Table 14. GSK Major Business
Table 15. GSK Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 16. GSK Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. GSK Recent Developments/Updates
Table 18. Pfizer Basic Information, Manufacturing Base and Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 21. Pfizer Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Pfizer Recent Developments/Updates
Table 23. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 24. Johnson & Johnson Major Business
Table 25. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 26. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Johnson & Johnson Recent Developments/Updates
Table 28. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 29. Takeda Pharmaceutical Company Limited Major Business
Table 30. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 31. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 33. BeiGene, Inc Basic Information, Manufacturing Base and Competitors
Table 34. BeiGene, Inc Major Business
Table 35. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 36. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. BeiGene, Inc Recent Developments/Updates
Table 38. Jiangsu Hengrui Pharmaceuticals Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 39. Jiangsu Hengrui Pharmaceuticals Co., Ltd Major Business
Table 40. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product and Services
Table 41. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments/Updates
Table 43. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 44. Global Prostate Cancer PARP Inhibitor Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 45. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 46. Market Position of Manufacturers in Prostate Cancer PARP Inhibitor Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 47. Head Office and Prostate Cancer PARP Inhibitor Drugs Production Site of Key Manufacturer
Table 48. Prostate Cancer PARP Inhibitor Drugs Market: Company Product Type Footprint
Table 49. Prostate Cancer PARP Inhibitor Drugs Market: Company Product Application Footprint
Table 50. Prostate Cancer PARP Inhibitor Drugs New Market Entrants and Barriers to Market Entry
Table 51. Prostate Cancer PARP Inhibitor Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 53. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 54. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 55. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 56. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 57. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 58. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 61. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 62. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 63. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 64. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 65. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 66. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 67. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 68. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 69. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 70. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 71. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 72. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 73. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 74. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 75. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 76. North America Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 77. North America Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 78. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 81. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 82. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 83. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 84. Europe Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 87. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 88. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 89. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 90. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 91. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 92. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 93. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 94. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 95. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 96. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 97. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 98. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 99. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 100. South America Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 101. South America Prostate Cancer PARP Inhibitor Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 102. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 103. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 104. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 105. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 106. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 107. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 108. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 109. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 110. Prostate Cancer PARP Inhibitor Drugs Raw Material
Table 111. Key Manufacturers of Prostate Cancer PARP Inhibitor Drugs Raw Materials
Table 112. Prostate Cancer PARP Inhibitor Drugs Typical Distributors
Table 113. Prostate Cancer PARP Inhibitor Drugs Typical Customers
List of Figures
Figure 1. Prostate Cancer PARP Inhibitor Drugs Picture
Figure 2. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Type in 2022
Figure 4. Lynparza Examples
Figure 5. Zejula Examples
Figure 6. Talzenna Examples
Figure 7. Fluzoparib Examples
Figure 8. PamiPali Examples
Figure 9. Other Examples
Figure 10. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 11. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Application in 2022
Figure 12. Hospital Examples
Figure 13. Specialty Clinic Examples
Figure 14. other Examples
Figure 15. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity (2018-2029) & (K Units)
Figure 18. Global Prostate Cancer PARP Inhibitor Drugs Average Price (2018-2029) & (US$/Unit)
Figure 19. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 20. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 21. Producer Shipments of Prostate Cancer PARP Inhibitor Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 22. Top 3 Prostate Cancer PARP Inhibitor Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Top 6 Prostate Cancer PARP Inhibitor Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 25. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Region (2018-2029)
Figure 26. North America Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. Europe Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. South America Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029) & (USD Million)
Figure 30. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Consumption Value (2018-2029) & (USD Million)
Figure 31. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 32. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Type (2018-2029)
Figure 33. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 34. Global Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 35. Global Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Application (2018-2029)
Figure 36. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 37. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 38. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 39. North America Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 40. North America Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Country (2018-2029)
Figure 41. United States Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Canada Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Mexico Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 45. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 46. Europe Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 47. Europe Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Country (2018-2029)
Figure 48. Germany Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. France Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. United Kingdom Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Russia Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Italy Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 54. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 55. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 56. Asia-Pacific Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Region (2018-2029)
Figure 57. China Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Japan Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Korea Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. India Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Southeast Asia Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Australia Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 64. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 65. South America Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 66. South America Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Country (2018-2029)
Figure 67. Brazil Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Argentina Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 70. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 71. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 72. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Consumption Value Market Share by Region (2018-2029)
Figure 73. Turkey Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Egypt Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Saudi Arabia Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. South Africa Prostate Cancer PARP Inhibitor Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Prostate Cancer PARP Inhibitor Drugs Market Drivers
Figure 78. Prostate Cancer PARP Inhibitor Drugs Market Restraints
Figure 79. Prostate Cancer PARP Inhibitor Drugs Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Prostate Cancer PARP Inhibitor Drugs in 2022
Figure 82. Manufacturing Process Analysis of Prostate Cancer PARP Inhibitor Drugs
Figure 83. Prostate Cancer PARP Inhibitor Drugs Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source

※参考情報

前立腺がんは、男性における最も一般的ながんの一つであり、その進行や転移によって患者の生存率や生活の質に大きな影響を与える疾患です。その治療にはさまざまなアプローチがありますが、最近の研究では前立腺がんに対するPARP阻害剤が注目を集めています。PARP（ポリ(ADP-リボース)ポリメラーゼ）阻害剤は、DNA修復に関与する酵素を標的とすることで、がん細胞の増殖を効果的に抑制することが期待されています。

まず、PARP阻害剤の定義について触れます。PARPはDNA損傷の修復に不可欠な役割を担う酵素であり、DNAが損傷を受けた際にその修復を行うことで、細胞の生存を助けています。PARP阻害剤はこの酵素の働きを阻害することにより、損傷したDNAが修復されない状態を作り出します。特に、BRCA1およびBRCA2遺伝子に変異を持つがん細胞は、DNA修復の能力が低下しているため、PARP阻害剤の影響を受けやすいのが特徴です。これによって、がん細胞は致命的な損傷を抱え、最終的には細胞死に至る可能性が高まります。

次に、PARP阻害剤の特徴を考えてみましょう。PARP阻害剤は主にがん細胞の特異的な弱点を突く形で作用します。このような特異性高い治療法は、周囲の正常な細胞には影響を及ぼさず、がん細胞を効率よく攻撃することが可能です。さらに、PARP阻害剤は特定の遺伝子変異と相互作用するため、個別化医療の一環として利用されることが多く、患者の遺伝子プロフィールに基づいた治療戦略が展開されています。

PARP阻害剤にはいくつかの種類があり、それぞれ異なる特徴を持っています。主要なPARP阻害剤には、オラパリブ、ナブテロパリブ、ルカパリブなどがあります。オラパリブは、BRCA変異を持つ卵巣がんや乳がんに対して承認されていることが多いですが、最近では前立腺がんに対しても効果が確認されつつあります。ナブテロパリブは、より新しいブレンドとして、様々な固形がんの治療において一定の成果を上げています。ルカパリブは、特にBRCA遺伝子に関連したがんに特化しており、その効果が評価されています。

用途については、PARP阻害剤は主に前立腺がんの治療において使用されます。特に治療抵抗性の高い前立腺がん患者に対して、PARP阻害剤は新たな治療オプションとして期待されています。特に、BRCA変異を持つ前立腺がん患者に対しては、PARP阻害剤は有効性が高いとされ、臨床試験において一定の成果が確認されています。治療計画としては、ホルモン療法や化学療法との併用も検討されており、より効果的な治療戦略が進められています。

関連技術としては、遺伝子検査が挙げられます。PARP阻害剤の効果は、がん細胞の遺伝子変異に依存するため、患者に対して適切な遺伝子検査を行うことが重要です。これにより、治療に最も適した患者を特定し、個別化したアプローチを推進することが可能となります。また、病理学や生物学の進展に従い、新たなバイオマーカーの発見がPARP阻害剤の効果を予測する手助けとなることが期待されています。

一方で、PARP阻害剤には副作用も存在します。一般的な副作用には、吐き気、疲労感、貧血、血小板減少などが挙げられ、これらは治療中の患者にとって重要な懸念材料となります。したがって、患者の状態や健康背景を考慮しながら、医師は治療法を選択する必要があります。適切なサポート体制を構築し、副作用の軽減を図ることも、治療成功の鍵となります。

今後の展望として、PARP阻害剤は前立腺がん治療における重要な選択肢として位置付けられるでしょう。臨床試験の成果がさらなる治療法の発展を促し、対象となる患者層も広がることが期待されます。PARP阻害剤の効果を最大限に引き出すためには、患者一人ひとりの遺伝子背景を考慮し、より細かな個別化治療が進んでいくことが求められます。また、新しい薬剤の開発や治療の融合が進む中で、前立腺がん治療における新たなパラダイムの形成が期待されています。これにより、より多くの患者が良好な治療結果を得られることを願うばかりです。前立腺がんのPARP阻害剤は、今後も研究と開発が進められ、がん治療の新たな時代を切り開く存在となるでしょう。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 前立腺がん治療装置のグローバル市場2023：体外照射装置、小線源治療装置、高密度焦点式超音波（HIFU）装置、凍結治療装置、ロボット支援手術装置
  • ホスホジエステラーゼ-5 阻害剤のグローバル市場2023：経口錠剤、経口液剤
  • ホスホジエステラーゼ-4 阻害剤のグローバル市場2023：経口、外用
  • 循環ガレクチン阻害剤のグローバル市場2023：天然、合成
  • 微小管阻害薬の世界市場2025-2031：重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23AG11533 )"前立腺がんPARP阻害剤のグローバル市場2023：リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他" (英文：Global Prostate Cancer PARP Inhibitor Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。